

AMENDMENTS TO THE CLAIMS:

This listing of claims replaces all prior versions of claims in the application.

Claims 1-10 (Canceled)

11. (Currently Amended) A method of treating an acute or chronic rejection reaction of in a xenograft transplantation recipient patient to a xenograft transplant, which comprises administering to the recipient ~~a patient~~ receiving the a xenograft a therapeutically effective amount of leflunomide product, wherein said product is N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxanilide or N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxycrotonamide.

12. (Previously Presented) The method of claim 11, wherein the xenograft is skin, heart, kidney, liver, bone, pancreas, or blood.

13. (Previously Presented) The method of claim 11, wherein the leflunomide product is administered at 10 mg/kg of body weight per day.